- Home
- MRBK vs ELDN Comparison
MRBK vs ELDN Comparison
Compare MRBK & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- ELDN
- Stock Information
- Founded
- MRBK 2004
- ELDN 2004
- Country
- MRBK United States
- ELDN United States
- Employees
- MRBK N/A
- ELDN N/A
- Industry
- MRBK Major Banks
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- MRBK Finance
- ELDN Health Care
- Exchange
- MRBK Nasdaq
- ELDN Nasdaq
- Market Cap
- MRBK 162.3M
- ELDN 164.1M
- IPO Year
- MRBK 2017
- ELDN N/A
- Fundamental
- Price
- MRBK $14.41
- ELDN $1.50
- Analyst Decision
- MRBK Buy
- ELDN Strong Buy
- Analyst Count
- MRBK 2
- ELDN 3
- Target Price
- MRBK $17.50
- ELDN $11.00
- AVG Volume (30 Days)
- MRBK 48.6K
- ELDN 4.2M
- Earning Date
- MRBK 10-23-2025
- ELDN 11-14-2025
- Dividend Yield
- MRBK 3.47%
- ELDN N/A
- EPS Growth
- MRBK 75.95
- ELDN N/A
- EPS
- MRBK 1.77
- ELDN N/A
- Revenue
- MRBK $109,758,000.00
- ELDN N/A
- Revenue This Year
- MRBK $26.84
- ELDN N/A
- Revenue Next Year
- MRBK $8.90
- ELDN N/A
- P/E Ratio
- MRBK $8.15
- ELDN N/A
- Revenue Growth
- MRBK 18.84
- ELDN N/A
- 52 Week Low
- MRBK $11.16
- ELDN $1.39
- 52 Week High
- MRBK $17.33
- ELDN $5.08
- Technical
- Relative Strength Index (RSI)
- MRBK 43.57
- ELDN 26.70
- Support Level
- MRBK $14.35
- ELDN $1.60
- Resistance Level
- MRBK $14.88
- ELDN $2.40
- Average True Range (ATR)
- MRBK 0.38
- ELDN 0.33
- MACD
- MRBK -0.01
- ELDN -0.24
- Stochastic Oscillator
- MRBK 30.46
- ELDN 4.04
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.